Aldosterone, aldosterone receptor blockers and chronic kidney disease
Abstract
Chronic kidney disease (CKD) is a worldwide public health problem and an important risk factor for cardiovascular events, morbidity and mortality. The renin-angiotensin-aldosteron system (RAAS) drugs, angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers contribute to a better evaluation of patients with CKD. Despite good efficacy of mentioned drugs, progressive decline of kidney function was observed, suggesting a hypothesis that both aldosterone activity related mechanism and some RAAS independent mechanisms may result in progressive kidney failure. The author of the article described the role of aldosterone and aldosterone receptor blockers in patients with CKD.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
